|
| Friday, March 29, 2024 |
|
|
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024 |
| Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), the dual orexin receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2024 by the PSJ. more info >> |
|
| Thursday, March 21, 2024 |
|
|
Lifenet and Eisai Co-Develop Dementia Insurance "be" |
| LIFENET INSURANCE COMPANY and Eisai Co., Ltd. announced today that they have co-developed Dementia Insurance "be", a dementia insurance that supports early detection and treatment of dementia and mild cognitive impairment (hereafter, "MCI") as one of the initiatives under the capital and business alliance agreement concluded in August 2022 for collaboration in dementia and other areas. more info >> |
|
|
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace |
| Eisai Co., Ltd. announced today that it has been selected for the first time by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as one of the Nadeshiko Brand 2024, as a listed company excelling in the promotion of women in the workplace. more info >> |
|
| Wednesday, March 6, 2024 |
|
|
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC to support C2N's efforts to expand the availability, accessibility, affordability and utilization of blood-based tests for the diagnosis of Alzheimer's disease (AD) in the U.S. more info >> |
|
|
エーザイ、早期アルツハイマー病の診断の簡便化を支援するためC2N Diagnostics LLCに出資 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、当社米国子会社エーザイ・インクが、C2N Diagnostics LLC（本社：米国ミズーリ州セントルイス 以下 C2N）による米国におけるアルツハイマー病（AD）の血液診断の実用化ならびに、アクセス、アフォーダビリティ、および利用の拡大に向けた取り組みを支援するため、同社に最大15百万米ドルの出資を決定したことをお知らせします。 more info >> |
|
| Thursday, February 29, 2024 |
|
|
エーザイ、第18回アルツハイマー・パーキンソン病学会（AD/PDTM2024）において、レカネマブをはじめとするアルツハイマー病に関する最新研究成果を発表 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、抗Aβプロトフィブリル＊抗体レカネマブ（一般名、製品名「レケンビ」、米国ブランド名「LEQEMBI」）をはじめとする当社のアルツハイマー病（AD）ポートフォリオに関する最新研究成果について、口頭発表10演題を含む合計18演題を、3月5日から９日までポルトガル・リスボンおよびバーチャルで開催される「第18回アルツハイマー・パーキンソン病学会（International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders：AD/PD™ 2024）において発表することをお知らせします。 more info >> |
|
| Wednesday, February 21, 2024 |
|
|
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050 |
| Eisai Co., Ltd. announced today that it has received approval to participate in the Japan Climate Initiative (JCI) Race to Zero Circle, which commits to achieve net zero* by 2050, as part of its mid- and long-term initiatives to reduce greenhouse gas (GHG) emissions. more info >> |
|
| Tuesday, February 20, 2024 |
|
|
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives |
| Eisai Co., Ltd. announced today that it has been selected for "Human Capital Leaders 2023" and "Human Capital Management Gold Quality" in the "Human Capital Survey 2023" jointly conducted by HR Technology Consortium, HR Research Institute (ProFuture Inc.) and MS&AD InterRisk Research & Consulting, Inc. more info >> |
|
| Friday, February 16, 2024 |
|
|
エーザイ、「メトジェクト(R)皮下注ペン」（一般名：メトトレキサート）が日本においてペン型自動注入器注射剤の承認を取得 |
| more info >> |
|
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan |
| Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate). more info >> |
|
|
|
|
